AstraZeneca PLC AZN.BA Stock
AstraZeneca PLC Price Chart
AstraZeneca PLC AZN.BA Financial and Trading Overview
AstraZeneca PLC stock price | 42170 ARS |
Previous Close | 31577 ARS |
Open | 32467.5 ARS |
Bid | 32000 ARS x N/A |
Ask | 32689 ARS x N/A |
Day's Range | 32121.5 - 33333 ARS |
52 Week Range | 214.5 - 33333 ARS |
Volume | 8.74K ARS |
Avg. Volume | 0 ARS |
Market Cap | 204.94T ARS |
Beta (5Y Monthly) | 0.162 |
PE Ratio (TTM) | 606.23706 |
EPS (TTM) | 53.07 ARS |
Forward Dividend & Yield | 10.83 (5.05%) |
Ex-Dividend Date | August 10, 2023 |
1y Target Est | N/A |
AZN.BA Valuation Measures
Enterprise Value | 49.96T ARS |
Trailing P/E | 606.23706 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 4607.0127 |
Price/Book (mrq) | 1333.6511 |
Enterprise Value/Revenue | 1122.966 |
Enterprise Value/EBITDA | 2836.749 |
Trading Information
AstraZeneca PLC Stock Price History
Beta (5Y Monthly) | 0.162 |
52-Week Change | N/A |
S&P500 52-Week Change | N/A |
52 Week High | 33333 ARS |
52 Week Low | 214.5 ARS |
50-Day Moving Average | 214.5 ARS |
200-Day Moving Average | 214.5 ARS |
AZN.BA Share Statistics
Avg. Volume (3 month) | 0 ARS |
Avg. Daily Volume (10-Days) | 0 ARS |
Shares Outstanding | 1.55B |
Float | 1.55B |
Short Ratio | N/A |
% Held by Insiders | 0% |
% Held by Institutions | 0% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 2.9 |
Trailing Annual Dividend Yield | 0.0091% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0.22950001 |
Last Split Factor | 2:1 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | June 30, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 13.85% |
Operating Margin (ttm) | 22.79% |
Gross Margin | 86.96% |
EBITDA Margin | 39.58% |
Management Effectiveness
Return on Assets (ttm) | 8.32% |
Return on Equity (ttm) | 16.81% |
Income Statement
Revenue (ttm) | 44.49B ARS |
Revenue Per Share (ttm) | 2.38 ARS |
Quarterly Revenue Growth (yoy) | 6.00% |
Gross Profit (ttm) | 35.73B ARS |
EBITDA | 17.61B ARS |
Net Income Avi to Common (ttm) | 6.16B ARS |
Diluted EPS (ttm) | 53.07 |
Quarterly Earnings Growth (yoy) | 405.00% |
Balance Sheet
Total Cash (mrq) | 5.81B ARS |
Total Cash Per Share (mrq) | 3.75 ARS |
Total Debt (mrq) | 30.79B ARS |
Total Debt/Equity (mrq) | 82.3 ARS |
Current Ratio (mrq) | 0.866 |
Book Value Per Share (mrq) | 24.124 |
Cash Flow Statement
Operating Cash Flow (ttm) | 10.18B ARS |
Levered Free Cash Flow (ttm) | 10.94B ARS |
Profile of AstraZeneca PLC
Country | Argentina |
State | N/A |
City | Cambridge |
Address | 1 Francis Crick Avenue |
ZIP | CB2 0AA |
Phone | 44 20 3749 5000 |
Website | https://www.astrazeneca.com |
Industry | Drug Manufacturers-General |
Sector(s) | Healthcare |
Full Time Employees | 83500 |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications; and collaboration with Cholesgen (Shanghai) Co.Ltd. to advance research and development in hypercholesterolemia and related metabolic diseases, as well as a collaboration with BioCity Biopharma to evaluate a monoclonal antibody for the treatment of advanced hepatocellular carcinoma. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Q&A For AstraZeneca PLC Stock
What is a current AZN.BA stock price?
AstraZeneca PLC AZN.BA stock price today per share is 42170 ARS.
How to purchase AstraZeneca PLC stock?
You can buy AZN.BA shares on the Buenos Aires exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for AstraZeneca PLC?
The stock symbol or ticker of AstraZeneca PLC is AZN.BA.
Which industry does the AstraZeneca PLC company belong to?
The AstraZeneca PLC industry is Drug Manufacturers-General.
How many shares does AstraZeneca PLC have in circulation?
The max supply of AstraZeneca PLC shares is 6.37B.
What is AstraZeneca PLC Price to Earnings Ratio (PE Ratio)?
AstraZeneca PLC PE Ratio is 794.61090000 now.
What was AstraZeneca PLC earnings per share over the trailing 12 months (TTM)?
AstraZeneca PLC EPS is 53.07 ARS over the trailing 12 months.
Which sector does the AstraZeneca PLC company belong to?
The AstraZeneca PLC sector is Healthcare.